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Abstract 
Curcumin, when used in a combination regimen in multiple myeloma patients, has comparable 
progression-free survival without the adverse effects of steroid-based combination therapies that is 
curcumin may be a viable alternative to corticosteroids in combination with an immunomodulatory drug 
or proteasome inhibitor. 
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1 |  INTRODUCTION
There are currently many promising strategies for manage-
ment of MM, including immunomodulatory drugs (IMiDs), 
proteasome inhibitors (PIs), or histone deacetylase inhibitors, 
but also novel strategies, such as small-molecule inhibitors, 
monoclonal antibodies, or chimeric antigen receptor (CAR) 
T cells.1,2 Treatment regimens typically involve a steroid, 
such as dexamethasone (Dex), used in combination with 
either an ImiD (ie, thalidomide, lenalidomide, or pomalid-
omide) or a PI (ie, bortezomib, carfilzomib, or ixazomib).3-7 
Despite its demonstrated effectiveness in treating MM, the 
administration of Dex remains a challenge, particularly in 
elderly patients, due to its side effects: fatigue, weight gain, 
fluid retention, poor impact on mental health, osteoporosis 
and hyperglycemia, or poor diabetic control.5
A randomized controlled trial of 1623 transplant-ineli-
gible MM patients has shown that continuous lenalidomide 
(revlimid) and Dex (Rd) were superior to either 18 cycles of 
Rd or a combination of melphalan, prednisone, and thalido-
mide (MPT).6 Compared to 18 Rd cycles, a 30% reduction 
in the risk of progression or death was observed when pa-
tients were treated with continuous Rd.6 Continuous therapy 
was also shown to be associated with a longer duration of re-
sponse and a longer median time to second-line antimyeloma 
therapy. However, continuous Rd for greater than 72 weeks 
was associated with an augmentation of adverse effects such 
as infection(s), thromboembolic events, and cataracts. These 
adverse effects were, at least partly, attributable to the Dex 
component of the regimen.6 Dex-related side effects have 
also been observed in other studies.4
Consequently, the challenge in MM management is to re-
tain the prolonged duration of response and median time to 
second-line chemotherapy associated with continuous ther-
apy while simultaneously avoiding the adverse effects as-
sociated with corticosteroid administration. Often, patients 
can be supported through induction therapy with high-dose 
steroids, but prolonged continuous therapy is more challeng-
ing. The clinical benefit associated with prolonged response 
duration and extended median time to the requirement for 
second-line chemotherapy is particularly significant in el-
derly patients who, in general, respond poorly to rescue 
therapy. The aim of this study, therefore, is to report our 
experience with curcumin, combined with either an IMiD 
or PI, in the treatment of older (>55  years) MM patients 
intolerant of Dex.
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Abstract
Curcumin, when used in a combination regimen in multiple myeloma patients, has 
comparable progression-free survival without the adverse effects of steroid-based 
combination therapies that is curcumin may be a viable alternative to corticosteroids 
in combination with an immunomodulatory drug or proteasome inhibitor.
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Curcumin is the primary active component of tur-
meric. It is a hydrophobic polyphenol extracted from the 
rhizomes.8 Curcumin displays a wide range of biological 
activities including anti-oxidant, anti-inflammatory, and 
cytotoxicity to numerous cancer cell types.9 Its anticancer 
effect has been attributed to regulation of multiple cell sig-
nalling pathways involved in cell proliferation and apopto-
sis.10,11 Curcumin has a demonstrated cytotoxic effect on 
myeloma activity12,13 as well as a synergistic effect when 
used in combination with an IMiD or PI.14,15 In a study 
by Wong et al,16 curcumin was shown to enhance the cy-
totoxic and chemo-sensitizing effects of lenalidomide by 
suppressing the expression of the cereblon (CRBN) gene, 
which is a primary target for IMiD drugs like thalidomide 
and lenalidomide.17 The same study also reported an en-
hanced reduction in the expression of the MRP gene, which 
encodes the multidrug resistant protein, when lenalidomide 
and curcumin are used together on H929 myeloma cell line. 
Recently, Allegra et al18 reported a synergism between car-
filzomib and curcumin toward induction of cytotoxicity on 
U266 myeloma cells. A combination of carfilzomib with 
curcumin leads to a significantly stronger downregulation 
of the NF-kB pathway.18
Banerjee et al19 report that eight different “protea-
some-adapted” cell lines (multiple myeloma and triple-neg-
ative breast cancer) exhibit strong synergistic toxicity upon 
treatment with a carfilzomib and curcumin combination. 
However, noncancerous cells did not exhibit the similar lev-
els of cytotoxicity thus conveying the fact that cancer cells 
with acquired proteasome resistance could be selectively tar-
geted by the curcumin-carfilzomib combination.
In this report, we describe our experience with the use 
of curcumin instead of Dex in combination therapy in MM 
patients intolerant of Dex.
2 |  METHODS
A total of 15 patients (>55 years) with multiple myeloma 
who were being treated with either an IMiD or PI plus 
Dex, who developed side effects determined to be due to 
the Dex, were selected to replace the Dex with curcumin 
and continue with their treatment. Patients were advised 
to take curcumin at a dose of 3-4 g daily of C3 complex 
curcumin. They were monitored at intervals ranging 
from 1 to 3  months. At each visit, blood and urine sam-
ples were collected and analyzed for markers of myeloma 
activity (ie, paraprotein, Hb, calcium, eGFR, and B2 mi-
croglob). Paraprotein levels were used as a measure of 
disease stability or progression. Bone marrow biopsies 
were performed at intervals as determined by the treating 
hematologist. Conventional cytogenetic analysis for each 
patient was performed at intervals as well as fluorescent 
in situ hybridization (FISH). Data are expressed as a mean 
(±1 SD).
3 |  RESULTS
There were fifteen MM patients intolerant of Dex in whom 
curcumin was used in combination with IMiD’s or PI’s. Of 
the fifteen, seven patients had a history of diabetes and three 
were grossly obese with a BMI > 40. Six patients had a his-
tory of mental health issues including anxiety/depression. 
Two patients with poorly controlled hypertension and sig-
nificant renal impairment (eGFR < 25) could not tolerate 
dexamethasone therapy. The characteristics of each patient 
at time of diagnosis, their treatment, and follow-up out-
comes as of June 2019 are illustrated in Table 1. There were 
six females and nine males with a mean age of 72  years 
(range 57-86) included in the study. There were 12 patients 
with IgG paraproteinemia (nine kappa and three lambda) 
and three patients with IgA paraproteinemia (two lambda 
and one kappa). The mean duration of disease was 6.9 
(±2.9) years, and the average duration of curcumin therapy 
was 6.1 (±2) years.
Individual biochemistry and erythrocyte sedimentation 
rate (ESR) data of each patient at diagnosis and follow-up are 
illustrated in Table 2. Table 3 illustrates mean (+SD) of the 
various markers of disease activity at diagnosis and at the end 
of the study period (June 2019). The mean paraprotein level 
at time of diagnosis was 29.9 (±18) g/L (n = 11) and at end 
of study was 18.7 (±13.3) g/L (n = 15). The mean peak para-
protein level observed throughout the course of care was 36.1 
(±19)  g/L (n  =  15). Mean plasmacytosis at diagnosis was 
39 (± 24.5)% (n = 15) and at end of study (June 19) was 16 
(±11.5) % (n = 10). We demonstrate that curcumin in com-
bination with other antimyeloma therapies was able to reduce 
paraprotein load by 38% and plasmacytosis by 59% over this 
study period. The mean hemoglobin at time of diagnosis 
was 123.3 (±14.9) g/L and at end of study period was 110.7 
(+15.7) g/L. Baseline ESR was 65.3 (±40.1) mm/hr and at 
end of study period was 62.1 (±36) mm/h At diagnosis, esti-
mated glomerular filtration rate (eGFR) was 70.1(±17.5) mL/
min and at end of study was 58.7(±24.1) mL/min. At diag-
nosis, calcium (Ca) was 2.46 (±0.28) mmol/L and at end of 
study was 2.40 (±0.17) mmol/L. Baseline beta 2 microglob-
ulin (B2M) was 3.9 (±2.4) mg/L and end of study was 5.3 
(+4.5) mg/L.
Table 4 illustrates the conventional cytogenetics and FISH 
of each patient. No high-risk cytogenetic abnormalities were 
detected in seven patients (1, 3, 4, 5, 9, 14, and 15). Eight 
patients had cytogenetic abnormalities that suggested higher 
risk disease (2, 6, 7, 8, 10, 11, 12, and 13).
Two patients (5, 9) developed diarrhea during the course 
of curcumin therapy. In patient 9, the diarrhea did not abate 
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T A B L E  1  Individual clinical data, therapy, paraprotein levels, and plasmacytosis at diagnosis and end of study (June 2019) of multiple 
myeloma patients intolerant of Dex in whom curcumin was used in combination with IMiD’s or PI’s
Patient 
no.
Age/
Sex Type Maintenance rx
PP at 
diagnosis
PP at 
Eos
% pc at 
diagnosis
% pc at 
Eos
Curc 
duration
1 71/F IgGK Tha/Dex/Bort/Cycloph/Clexane/Len/Pam/IVIG/
Pom
40 38 7 x 7
2 62/M IgGL Tha/Cycloph/Bort/Len/Pom/Ixazo + ASCT 8 30 10 31 5
3 61/M IgGL Tha/Dex/Len/Pam/IVIG/ +ASCT 16 20 71 37 6
4 78/M IgGK Tha/Dex/Len/Pam/IVIG/ +ASCT 44 50 52 5 3
5 86/F IgGK Pam/Melph/Pred/Len/Dex x 4 27 x 9
6 82/M IgGK VMP/Dex/IVIG/Pam x 19 15 14 6
7 77/M IgGK Len/Pam/IVIG 21 5 19 x 3
8 72/F IgAL Len. 11 14 27 17 6
9 71/M IgGK Len/Alloprinol/Diamicron/Janovia/Zometa/
IVIG
20 3 60 x 7
10 58/F IgAK Bort/Tha/Cycophos/Dex/Pam/Pamisol/IVIG + 
ABMT
33 21 55 5 6
11 57/M IgGK Pam/IVIG/Tha/Dex/Bort/Len/Cycloph + ASCT x 11 71 15 9
12 64/F IgGK Bort/Cycloph/Dex/Tha/Len/Pom x 12 35 x 4
13 85/F IgGL Melph/Tha/Aredia/Dex/Velcade/ Pom 69 30 45 11 9
14 75/M IgGK CyBorD/Velcade/Revlimid 25 14 16 23 7
15 66/M IgAL CyBord/ABMT/ Rev 42 9 70 2 6
Abbreviations: %pc, percentage plasma cells; ABMT, Autologous Bone Marrow Transplant; ASCT, Autologous Stem Cell Transplant; Bort, Bortezomib (Velcade); 
Curc, curcumin; Cycloph, Cyclophosomide; Dex, Dexamethasone; Eos, end of study; IVIG, Intravenous Immunoglobulin Infusion; Len, Lenalidomide (Revlimid); 
Melp, Melphalan; Mitox, Mitoxantrone; Pam, Pamidronate; Pom, Pomalidomide; PP, Paraproteinaemia; Pred, Prednisolone; Tha. Thalidomide; Vin, Vincristine; 
VMP, Bortezomib + Melphalan +Prednisone; x, information not available.
T A B L E  2  Individual biochemistry at diagnosis and end of study (June 2019)
Patient no. Hb at dx Eos Hb Esr at dx Eos esr eGFR at dx Eos eGFR Ca at dx Eos ca B2M at dx Eos B2M
1 122 102 73 16 58 50 2.51 2.52 3.9 6.9
2 126 101 52 94 90 90 2.46 2.37 2.1 3.3
3 118 113 38 88 90 90 2.09 2.34 1.8 3
4 97 85 98 120 67 24 2.64 2.95 6.9 19.4
5 123 121 49 61 62 30 2.42 2.33 2.7 3.6
6 125 98 26 120 65 38 2.22 2.33 1.8 6.4
7 98 91 95 62 87 42 2.3 2.19 3.8 4.9
8 143 103 31 38 84 44 2.4 2.29 2.9 2.4
9 130 112 19 30 71 31 2.5 2.4 1.8 3.6
10 116 109 120 90 74 77 2.66 2.33 3.7 2.2
11 143 124 111 56 57 86 2.23 2.38 2.7 1.9
12 126 108 30 27 90 90 2.34 2.35 8.6 6.5
13 126 119 111 79 24 50 2.41 2.39 9.1 10.2
14 148 148 7 3 71 65 2.44 2.45 3.7 3.3
15 108 126 120 48 62 73 3.3 2.34 3 2.2
Abbreviations: B2M, beta 2 microglobulin (normal range 0-3 mg/L); Ca, calcium (normal range 2.15-2.55 mmol/L); dx, diagnosis; eGFR, estimated glomerular 
filtration rate (normal range > 90 mL/min); Eos, end of study; esr, erythrocyte sedimentation rate (normal range 0-29 mm/h); Hb, hemoglobin (normal range 
119-160 g/L).
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following curcumin suspension suggesting an alternative 
cause. When rechallenged with curcumin, the patient did not 
develop diarrhea. Patient no. 5 was managed by temporarily 
suspending curcumin therapy and reducing the dose.
Of the 15 patients, 12 remain alive at the time of writ-
ing up the case series (June 2019). Three patients (1, 3, 4) 
had died. One patient (no. 1) developed dementia and ceased 
therapy and died. She had been on curcumin therapy for 
7 years. Patient no. 3 had spinal involvement of his disease 
and received radiation. He unfortunately progressed to para-
plegia and subsequent death. He had been taking curcumin 
for 6 years. Patient no. 4 (age 79) had a poor prognosis due to 
cardiac issues. He had been taking curcumin for 3 years and 
died of an infection at the end of this period. The remaining 
12 patients are considered to be in a stable condition and are 
progressing well.
T A B L E  3  Disease progression markers and biochemistry of MM 
patients at diagnosis and at end of study period (Mean ± SD)
Variables At diagnosis Eos (June 19)
Plasma cells (%) 38.3 ± 23.4 15.6 ± 11.5
Paraprotein (g/L) 29.9 ± 18 18.7 ± 13.3
Hemoglobin 
(119-160 g/L)
123.3 ± 14.9 110.7 ± 15.7
B 2 microglobulin 
(0-3 mg/L)
3.9 ± 2.4 5.3 ± 4.5
Calcium 
(2.15-2.55 mmol/L)
2.46 ± 0.28 2.4 ± 0.17
ESR (0-29 mm/h) 65.3 ± 40.4 62.1 ± 36
eGFR (>90 mL/min) 70.1 ± 17.5 58.7 ± 24.1
Abbreviations: eGFR, estimated glomerular filtration rate; Eos, end of study; 
ESR, erythrocyte sedimentation rate.
T A B L E  4  Cytogenetics and FISH (fluorescent in situ hybridization) of each patient
Patient no. Cytogenetics Findings
1 Normal Cytogenetic studies and FISH analysis did not reveal any high-risk abnormalities.
2 Normal Cytogenetic studies and FISH analysis consistent with high-risk disease: Deletion of the TP53 locus 
at 17p13 detected (2019), but had not appeared on earlier studies (2017, 2016, 2014, and 2012).
Gain of CKS1B with 3-4 copies of 1q21 detected (2016)
3 Normal Cytogenetic studies and FISH analysis did not reveal any high-risk abnormalities.
4 Normal Cytogenetic studies and FISH analysis did not reveal any high-risk abnormalities. (trisomy p53 
detected 2014 but lost by 2015)
5 Normal Cytogenetic studies and FISH analysis did not reveal any high-risk abnormalities.
6 45,X,-Y[4]/46,XY[26] Cytogenetic studies and FISH analysis consistent with high-risk disease: Gain of CKS1B with three 
copies of 1q21 detected (2014) and still present on most recent study (2017).
7 Normal Cytogenetic studies and FISH analysis consistent with high-risk disease: Gain of CKS1B with three 
copies of 1q21 detected (2016).
8 Normal Cytogenetic studies and FISH analysis consistent with high-risk disease: Gain of CKS1B with three 
copies of 1q21 detected.
Trisomy p53 detected (2014), but not detected on two prior studies (2014, 2013) or on subsequent 
studies (2016, 2017).
9 Normal Cytogenetic studies and FISH analysis did not reveal any high-risk abnormalities.
10 45,X,-X[4]/46,XX[26] Cytogenetic studies and FISH analysis consistent with high-risk disease: t(4;14) IGH/FGFR3 
translocation detected (2016 ,2017, and 2019). Gain of CKS1B with 3-4 copies of 1q21 was detected 
(2016). Tetrasomy (2019)
11 Normal Cytogenetic studies and FISH analysis consistent with high-risk disease: Deletion of the TP53 locus 
at 17p13 detected (2017)
12 Normal Cytogenetic studies and FISH analysis consistent with high-risk disease: Gain of CKS1B with three 
copies of 1q21 detected. A translocation involving the IGH locus at 14q32 was detected, but the 
translocation partner is unknown. t(4;14) and t(14;16) were not detected. These findings were not 
present in 2012 study but had developed by 2015 and were still present in 2016 and 2018 studies.
13 45,X,-X[3]/46,XX[24] Cytogenetic studies and FISH analysis consistent with high-risk disease: Gain of CKS1B with three 
copies of 1q21 (2018), and also a translocation involving the IGH locus at 14q32 was detected, but 
the translocation partner is unknown. t(4;14) and t(14;16) were not detected. Earlier studies (2015, 
2013, 2012, 2011, and 2009) were normal.
14 Normal Cytogenetic studies and FISH analysis did not reveal any high-risk abnormalities.
15 Normal Cytogenetic studies and FISH analysis did not reveal any high-risk abnormalities.
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4 |  DISCUSSION/CONCLUSION
Previous studies carried out in our clinics have demonstrated 
that oral administration of curcumin, even at high doses (up 
to 8 g daily), is well tolerated and can decrease the parapro-
tein load, free light chains, bone turnover, and % plasma cell 
dyscrasia in a selected group of patients with multiple my-
eloma precursor disease that is monoclonal gammopathy of 
undetermined significance (MGUS) and smoldering multiple 
myeloma (SMM).20-23
The multitude of published studies, including an in vitro 
study carried out in our laboratory,16 suggest that curcumin 
can potentiate not only the cytotoxic effect of multiple 
agents used in the treatment of MM, but also enhance the 
chemo-sensitizing effects of these agents. The implications 
arising from these observations may be of important clinical 
benefit: i) curcumin studies can be designed to assess the ad-
ditive antimyeloma effects of curcumin to the current treat-
ment protocols and ii) curcumin may be used as an alternative 
to corticosteroids in such protocols.
We show here that curcumin may act as a steroid-sparing 
agent in patients with MM who are intolerant of Dex. We 
demonstrate that curcumin in combination with other antimy-
eloma therapies was able to reduce paraprotein load by 38% 
and plasmacytosis by 59% over this study period. Multiple 
myeloma is a heterogenous disease from a cytogenetic ab-
normalities point of view.24 Eight of the 15 patients demon-
strated high-risk cytogenetic and FISH abnormalities with 
many of these showing evolution during the course of their 
illness. While three patients died during the course of this 
study, none of these had high-risk cytogenetic abnormalities. 
Some of the surviving patients do have high-risk cytogenetic 
and FISH abnormalities and despite this, continue to do well 
on the combination therapy.
This is the first reported case series of patients with MM 
who have been treated with adjuvant curcumin as opposed 
to Dex in combination with other antimyeloma agents. 
Curcumin-based combination therapies may be capable of 
stabilizing disease progression without the adverse effects 
associated with steroid use. In our experience, the only 
observed side effect of curcumin is diarrhea which can be 
managed by either temporarily suspending therapy or re-
ducing the dose. Therefore, curcumin can be considered to 
have comparatively minimal adverse effects and superior 
tolerability to typical steroid medications, such as com-
monly used dexamethasone.
Curcumin has been reported to induce anticancer and 
antiproliferative activity via multiple pathways including in-
duction of apoptosis by caspase activation, downregulation 
of essential transcription factors like NF-kB, inhibition of 
c-Jun N-terminal kinase (JNK), and protein tyrosine kinases 
and downregulation of growth factor receptors like HER2 
and EGFR.10 Banerjee et al19 establish that impairment of 
proteasome activity by DYRK2 inhibition is a major mecha-
nism of action for curcumin in the context of the alleviation of 
proteasome-dependent neoplastic malignancies such as MM.
Consequently, curcumin possesses the potential to impede 
myeloma activity and improve the quality of life in MM pa-
tients. Further randomized controlled trials should aim to elu-
cidate and replicate the findings of this study.
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